Passionate to deliver valuable medicines to patients in need

RDP Pharma is a privately held biotech, dedicated to the goal that our products will deliver valuable medicines to patients in need.

Mastering the Unstructured: Rationally Degrading IDR Proteins

Historically, intrinsically disordered region (IDR) proteins were considered undruggable due to their lack of a stable structure, which made traditional drug targeting methods ineffective. RDP Pharma has overcome this longstanding challenge with its proprietary PromptDegrader™ platform, designed specifically to identify and degrade disease-relevant IDRs. This breakthrough opens new therapeutic possibilities for conditions previously thought to be untreatable.  

Innovation & Vision

At RDP Pharma AG, our vision is a world where fewer diseases remain untreatable. Despite decades of research, serious conditions like cancer continue to challenge modern medicine. These diseases are often driven by proteins with intrinsically disordered regions (IDRs) such as MYC, which is involved in approximately 70% of all human cancers. Similarly, autoimmune diseases like multiple sclerosis, which drastically reduce quality of life, neurodegenerative diseases like ALS, which rob patients of their mobility, and rare diseases that force children to undergo numerous surgeries, all remain significant obstacles.

Unlike most proteins that have stable, puzzle-piece-like structures, IDR proteins are dynamic, constantly shifting shape to support different cellular functions—much like chameleons. This flexibility is essential for processes like cell division and immune regulation, but when these proteins malfunction, the consequences can be severe.

Because of their shifting structures, IDRs have long been considered “undruggable,” making the development of targeted therapies incredibly difficult—like trying to catch a cloud.

Our answer to this challenge is the PromptDegrader™ (Proteasomal Oral Monovalent Protein Targeting) platform, which opens the door to entirely new treatment possibilities.

Our Lab in Tulln, Austria